GRADE Study Group: Clinical Trials

1 trial sponsored by GRADE Study Group, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Completed 1

Follow GRADE Study Group: new trials by email

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide) - Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Phase 3CompletedGRADE Study Group78502013-05-012026-02-10

Conditions studied

Diabetes Mellitus, Type 2 (1)

Interventions

Dipeptidyl-Peptidase IV Inhibitors (1)  ·  Insulin Glargine (1)  ·  Liraglutide (1)  ·  Sitagliptin Phosphate (1)  ·  Sulfonylurea Compounds (1)  ·  glimepiride (1)

Countries

United States (1)

Top investigators

David M Nathan, MD (1)

Results publications

PMID 23690531, PMID 28213915, PMID 31368793, PMID 31391203, PMID 31393176, PMID 32139384, PMID 32450102, PMID 33288412, PMID 33334808, PMID 33752962, PMID 33766761, PMID 34285097, PMID 34531242, PMID 34556408, PMID 34780485, PMID 34971663, PMID 35061024, PMID 36129996, PMID 36129997, PMID 36549506, PMID 36999229, PMID 37094945, PMID 37213109, PMID 37329282, PMID 37368512, PMID 37394014, PMID 37756542, PMID 38190619, PMID 38190625, PMID 38194519, PMID 38211595, PMID 38227900, PMID 38252848, PMID 38252886, PMID 38285957, PMID 38333889, PMID 38344820, PMID 38354481, PMID 38416773, PMID 38837240, PMID 39312277, PMID 39546502, PMID 39951058, PMID 39963952, PMID 39977640, PMID 39998948, PMID 40267365, PMID 40315175, PMID 40388190, PMID 40424051

NIH funding

U01DK098246 (1)